Yes, compounded tirzepatide remains available to Georgia residents through telehealth in 2026, but the legal basis changed after the FDA declared the national tirzepatide shortage resolved in October 2024. Before that, 503A pharmacies could compound essentially-a-copy versions for anyone who wanted a lower-cost alternative. Now, compounding must be tied to a documented, patient-specific clinical need — not simply cost preference. Georgia's telemedicine rules don't require an in-person visit for a non-controlled medication like tirzepatide, but they do require a Georgia-licensed (or Georgia telemedicine-licensed) practitioner and an examination equivalent in quality to an in-person visit. The pharmacy shipping to you must also hold a Georgia non-resident pharmacy registration.
For several years, compounded semaglutide and tirzepatide were widely available because both medications sat on the FDA's official drug shortage list — a status that let 503A and 503B compounding pharmacies legally produce close copies of the commercial products for any patient who wanted a lower-cost path to treatment. That changed in 2024 and 2025.
What this means in practice: 503A pharmacies (like Luma Health's pharmacy partner, VialsRX) can still legally compound tirzepatide and semaglutide, but only when there's a documented, patient-specific reason the FDA-approved commercial product doesn't meet — for example, a needed strength or formulation the commercial product doesn't offer, an intolerance to an inactive ingredient in the brand pen, or another individualized clinical justification a prescriber documents at the time of evaluation. It's no longer legally sufficient for a pharmacy to compound a copy of Zepbound simply because a patient wants a lower price. Luma Health's clinical team at Wasef Health, PC documents the patient-specific basis for each compounded prescription as part of your evaluation — this is a normal part of intake, not an obstacle, but it does mean eligibility is determined case by case rather than guaranteed for every applicant.
The April 2026 proposal specifically targets the 503B bulks list, which governs large-scale outsourcing facilities rather than the patient-specific 503A pathway VialsRX operates under — so it's a narrower, more indirect risk to Luma Health's model than it is to platforms relying on 503B bulk supply. Still, this is an evolving regulatory area, and Georgia residents evaluating any compounded GLP-1 provider should ask directly what legal basis the pharmacy is compounding under before enrolling.
Georgia treats the patient's location, not the provider's, as the place of practice — if a clinician is treating someone physically located in Georgia, Georgia's rules apply even if the clinician is licensed elsewhere, provided they hold either a full Georgia license or a Georgia Telemedicine License under O.C.G.A. § 43-34-31.1.
Semaglutide and tirzepatide are not controlled substances, so the stricter in-person exam requirement that applies to controlled-substance prescribing in Georgia does not apply here. Instead, the Georgia Composite Medical Board's general telemedicine practice rule governs: the treating practitioner must be Georgia-licensed (or hold a Georgia Telemedicine License), your patient history must be available to them, and the remote examination must use technology and clinical judgment equivalent to what an in-person exam would provide. In practice, this means a synchronous, thorough intake and clinician review — not a same-day rubber-stamp form.
Any pharmacy dispensing to a Georgia resident from out of state must hold a Georgia non-resident pharmacy registration through the Georgia Board of Pharmacy — this is a real, separate registration from the pharmacy's home-state license, and it's worth confirming before you pay anyone. VialsRX, Luma Health's compounding pharmacy, is licensed by the Texas State Board of Pharmacy (License #35264), independently verifiable at pharmacy.texas.gov before you enroll.
If a provider can't tell you which pharmacy is preparing your medication, or whether that pharmacy holds the registration needed to ship into Georgia, that's a meaningful red flag worth taking seriously before paying anything.
Georgia Medicaid does not cover GLP-1 medications for weight loss — coverage exists only for type 2 diabetes indications, with prior authorization. Commercial insurers operating in Georgia generally require prior authorization and often step therapy for weight-loss GLP-1 coverage, consistent with the national pattern. For patients without applicable coverage, cash-pay compounded pricing in the Georgia telehealth market for tirzepatide commonly runs in the wider $199–$399/month range depending on provider and dose tier — Luma Health's flat $297/mo (all doses, no tier changes) sits within that range with the added benefit of predictable pricing regardless of dose escalation.
| Option | Monthly cost | Notes |
|---|---|---|
| Zepbound (brand, cash-pay) | ~$1,060–$1,350/mo | FDA-approved; savings card may reduce cost with qualifying insurance |
| Georgia telehealth compounded market (general range) | ~$199–$399/mo | Varies by provider, dose tier, and membership structure |
| ★ Luma Health compounded tirzepatide | $297/mo flat | All doses, no tier changes, no membership fee, VialsRX TX#35264 |
Luma Health prescribes compounded tirzepatide ($297/mo flat) and semaglutide ($197/mo flat) to eligible Georgia residents. VialsRX (TX Board #35264) — independently verifiable before you pay. All 50 states.
Start With Luma Health →Yes, but the legal basis narrowed after the FDA declared the tirzepatide shortage resolved in October 2024. Compounding is still legal when a licensed 503A pharmacy prepares a patient-specific formulation for a documented clinical need — it's no longer legally sufficient to compound a plain copy of the commercial product just because a patient wants a lower price. Ask any provider directly what basis they're compounding under.
No. Tirzepatide is not a controlled substance, so Georgia's stricter in-person exam requirement for controlled-substance prescribing doesn't apply. A synchronous telehealth evaluation by a Georgia-licensed (or Georgia Telemedicine-licensed) practitioner that meets the Board's standard for a remote exam is sufficient.
No. Georgia Medicaid does not cover GLP-1 medications for the weight-loss indication; coverage is available only for type 2 diabetes with prior authorization. If you're on Georgia Medicaid and specifically need tirzepatide for weight management, cash-pay compounded or brand options are currently the realistic paths.
Any pharmacy dispensing to a Georgia address from out of state must hold a Georgia non-resident pharmacy registration through the Georgia Board of Pharmacy. This is separate from the pharmacy's home-state license. Ask your provider to confirm this registration is current before you pay.
The proposal targets the 503B outsourcing-facility bulks list, which governs large-scale bulk compounding — it's a narrower issue for patient-specific 503A pharmacies like VialsRX, which prepare medication per individual prescription rather than from bulk supply. The public comment period closed June 29, 2026, and a final rule is still pending. This is an evolving area worth checking on directly with any provider you're evaluating.
The telehealth rules themselves apply statewide — there's no different legal standard for Atlanta versus rural south Georgia. In-person obesity medicine specialists are more concentrated in Atlanta, Savannah, Augusta, and Columbus, but telehealth access to a Georgia-licensed prescriber is the same regardless of where in the state you live.
Timing depends on your intake completion and clinician review, followed by VialsRX preparation and shipping with tracking. Because compounding now requires documenting a patient-specific clinical basis rather than a same-day automatic approval, plan for your evaluation to involve a genuine clinical review rather than an instant rubber-stamp — that's a feature of doing this correctly under current rules, not a delay to work around.